U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07464808) titled 'Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management' on Jan. 24.
Brief Summary: This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients
Study Start Date: Nov. 28, 2025
Study Type: INTERVENTIONAL
Condition:
Venous Thromboembolic Event
Intervention:
OTHER: follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay
follow up vte incidence and routine clexan dose modification
OTHER: follow up venous thromb...